Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

Eli Lilly and Company (LLY) will report first-quarter 2024 results on Apr 30, before market open.The Zacks Consensus Estimate for this drug giant’s first-quarter revenues is pegged at $8.81 billion, while the same for earnings per share is $2.53 per share, both indicating significant increases from the year-ago quarter.In the first quarter, top-line growth is expected to have been driven by strong demand for Lilly’s new tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. The Za ...